Baillie Gifford & Co
PTCT icon

Baillie Gifford & Co’s PTC Therapeutics PTCT Stock Holding History

Baillie Gifford & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-278
Closed -$13.5K – 404
2023
Q1 		$13.5K Buy
278
+32
+13% +$1.46K ﹤0.01% 377
2022
Q4 		$9.39K Hold
246
– – ﹤0.01% 418
2022
Q3 		$12K Hold
246
– – ﹤0.01% 395
2022
Q2 		$10K Hold
246
– – ﹤0.01% 411
2022
Q1 		$9K Hold
246
– – ﹤0.01% 446
2021
Q4 		$10K Hold
246
– – ﹤0.01% 448
2021
Q3 		$9K Hold
246
– – ﹤0.01% 458
2021
Q2 		$10K Hold
246
– – ﹤0.01% 436
2021
Q1 		$12K Hold
246
– – ﹤0.01% 391
2020
Q4 		$15K Buy
+246
New +$14.5K ﹤0.01% 350

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co's PTCT Position: Q2 2023 in Review

Baillie Gifford & Co sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 278 shares — an estimated $13.5K sold.

Baillie Gifford & Co first reported a position in PTCT in Q4 2020 and held it in 10 quarters. The position peaked at $15K in Q4 2020. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

  • Baillie Gifford & Co reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 278 PTC Therapeutics shares in Q2 2023, an estimated $13.5K.
  • Baillie Gifford & Co first reported a position in PTC Therapeutics in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's PTC Therapeutics position peaked at $15K in Q4 2020.
  • 204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.